We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

USAC:NYSEUSA Compression Partners, LP Analysis

Data as of 2026-09-20 - not real-time

$26.87

Latest Price

4/10Risk

Risk Level: Medium

Executive Summary

USA Compression Partners, LP is priced at $26.87 and its moving averages line up in bullish order, the shorter sitting above the longer. Over a rolling month the price has gained 3.0%. With RSI at 50.6 the momentum picture is neutral, alongside a bearish MACD signal. Price has been bracketed by support at $26.00 and resistance at $27.93.
The shares look overvalued, trading on 25.1 times earnings above a sector average of 17.8. Consensus targets land 11.6% above where the shares trade now. Revenue is growing at 36.8% on a 12.4% profit margin. The 7.82% dividend yield looks stretched against payout coverage.
Risk scores 4 out of 10, which is moderate for this asset class. With 30-day volatility of 21.3%, a beta of 0.15 and a maximum drawdown of 18.1%, position sizing matters here. The wider market backdrop reads extreme greed at 95 on the fear-greed composite.
The horizons diverge: buy near-term but hold on a long view, at 2/10 conviction over the longer horizon.

Top Market Events

Strong quarterly results driven by strategic acquisition, with 50% of 2027 new units already contracted amid robust...DALLAS, September 10, 2026--USA Compression Partners, LP NYSE: USAC the "Partnership" today announced the pricing of a...Why USA Compression Partners is back on investor radars USA Compression Partners USAC has drawn fresh attention after...

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 4/10

Key Factors

  • Short-term moving averages stacked above long-term ones
  • Trading above the 200-day average of 26.56
  • MACD momentum is negative

Medium Term

1–3 years
Neutral
Model confidence: 3/10

Key Factors

  • Short-term moving averages stacked above long-term ones
  • P/E of 25.1 versus sector average of 17.8
  • Dividend yield of 7.82% looks stretched against payout coverage

Long Term

> 3 years
Neutral
Model confidence: 2/10

Key Factors

  • P/E of 25.1 versus sector average of 17.8
  • Dividend yield of 7.82% looks stretched against payout coverage
  • Analyst targets imply +11.6% versus the current price

Key Metrics & Analysis

Financial Health

Revenue Growth36.80%
Profit Margin12.43%
P/E Ratio25.1
ROE122.35%
ROA7.15%
Debt/Equity1030.25
P/B Ratio13.6
Op. Cash Flow$447.2M
Free Cash Flow$284.3M
Industry P/E17.8

Technical Analysis

TrendBullish
RSI50.6
Support$26.00
Resistance$27.93
MA 20$26.99
MA 50$26.61
MA 200$26.56
MACDBearish
VolumeIncreasing
Fear & Greed Index94.98

Valuation

Fair Value$45.67
Target Price$30.00
Upside/Downside11.65%
GradeOvervalued
TypeBlend
Dividend Yield7.82%

Risk Assessment

Beta0.15
Volatility21.34%
Sector RiskHigh
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.